Monitor for future updates on trial initiation, patient enrollment progress, and any interim data. The success of this pivotal trial will be critical for FDA clearance and potential commercialization in the multi-billion-dollar insomnia market.
Price Chart
Executive Summary
Nexalin Technology announced the advancement of its planned pivotal clinical trial for the HALO Clarity device to treat moderate to severe insomnia, designed to support a future de novo FDA submission. The 150-patient, triple-blinded, sham-controlled study will be conducted in collaboration with Lindus Health using a decentralized model via Nexalin's NeuroCare virtual clinic.
Key Facts
- Nexalin is advancing a pivotal clinical trial for HALO Clarity, a device targeting moderate to severe insomnia.
- The study is a 150-patient, randomized, triple-blinded, sham-controlled trial to support a de novo FDA submission.
- Trial will be conducted in collaboration with Lindus Health, a full-service clinical research organization.
- Study will be fully decentralized, with remote treatment and assessment via Nexalin's NeuroCare virtual clinic.
- HALO Clarity uses Nexalin's proprietary 15 mA Deep Intracranial Frequency Stimulation (DIFS™) technology.
- The device has already received regulatory approvals in China, Brazil, Oman, and Israel for insomnia and related indications.
- The filing contains forward-looking statements about the trial, regulatory strategy, and commercial potential.
Financial Impact
No financial impact disclosed; this is a clinical development update with no immediate revenue or cost implications.
Risk Factors
- Clinical trial may face delays or fail to meet endpoints.
- FDA may not accept or approve the de novo submission.
- Device may face competition from existing insomnia treatments.
- Company may require additional funding to complete the trial and regulatory process.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-001634 |
| Document: nexalintec_ex99-1.htm | 0001829126-26-001634 |
| Document: 0001829126-26-001634-index-headers.html | 0001829126-26-001634 |
| Document: 0001829126-26-001634-index.html | 0001829126-26-001634 |
| Document: 0001829126-26-001634.txt | 0001829126-26-001634 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | EFFECT | $2.35 | awaiting T+20 | — | $1.71 (+27.23%) |
Oct 8, 2026 17d ago | S-1/A | $3.63 | awaiting T+20 | — | $1.71 (+52.89%) |
Oct 1, 2026 24d ago | 8-K | $5.73 | awaiting T+20 | — | $1.71 (−70.16%) |
Oct 1, 2026 24d ago | 8-K | $5.73 | awaiting T+20 | — | $1.71 (−70.16%) |
Sep 2, 2026 7w ago | 8-K | $5.36 $4.28 | ▼ −20.15% | ▼ −19.03% | $1.71 (−68.10%) |
Aug 27, 2026 8w ago | 8-K | $0.2548 $0.1463 | ▼ −42.57% | ▼ −42.60% | $1.71 (+571.11%) |
Aug 17, 2026 10w ago | 8-K | $0.3400 $0.1617 | ▲ +52.45% | ▲ +50.47% | $1.71 (−402.94%) |
Jun 10, 2026 19w ago | Press Release | $0.4590 $0.4607 | ▲ +0.37% | ▼ −3.70% | $1.71 (+272.55%) |
May 19, 2026 22w ago | 8-K | $0.3350 $0.3680 | ▲ +9.85% | ▲ +9.11% | $1.71 (+410.45%) |
May 19, 2026 22w ago | Press Release | $0.3210 $0.3930 | ▲ +22.43% | ▲ +21.44% | $1.71 (+432.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers